Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-08-02
2011-08-02
Navarro, Albert (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A
Reexamination Certificate
active
07989608
ABSTRACT:
An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA.
REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5521063 (1996-05-01), Summerton et al.
patent: 5698685 (1997-12-01), Summerton et al.
patent: 5892023 (1999-04-01), Pirotzky et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 6784291 (2004-08-01), Iversen et al.
patent: 7468418 (2008-12-01), Iversen et al.
patent: 7807816 (2010-10-01), Wilton et al.
patent: 2002/0049173 (2002-04-01), Bennett et al.
patent: 2003/0224353 (2003-12-01), Stein et al.
patent: 2006/0276425 (2006-12-01), Mourich et al.
patent: 2006/0287268 (2006-12-01), Iversen et al.
patent: 2007/0111962 (2007-05-01), Mourich et al.
patent: 2007/0122821 (2007-05-01), Iversen et al.
patent: 2007/0155685 (2007-07-01), Schlingensiepen
patent: 2009/0082547 (2009-03-01), Iversen et al.
patent: 2009/0088562 (2009-04-01), Weller et al.
patent: 2009/0099066 (2009-04-01), Moulton et al.
patent: 2009/0110689 (2009-04-01), Mourich et al.
patent: 2010/0130591 (2010-05-01), Sazani et al.
patent: 2010/0184670 (2010-07-01), Mourich et al.
patent: WO 01/49775 (2001-07-01), None
patent: WO 01/72765 (2001-10-01), None
patent: WO 01/83740 (2001-11-01), None
patent: WO 2006/000057 (2006-01-01), None
patent: WO 2006/086667 (2006-08-01), None
patent: WO 2006/108241 (2006-10-01), None
patent: WO 2010/048586 (2010-04-01), None
patent: WO 2010/080554 (2010-07-01), None
Gewirtz et al (PNSA USA vol. 93, pp. 3161-3163, 1996).
The International Search Report and Written Opinion for PCT application PCT/US2008/088339, search report dated Jun. 4, 2009, 13 pages (2009).
Akdis, C. A. and Blaser, K., “Mechanisms of interleukin-10-mediated immune suppression.”Immunology, 103(2):131-6 (2001).
Banchereau, J. and A. K. Palucka, “Dendritic cells as therapeutic vaccines against cancer.”Nature Reviews Immunology, 5(4):296-306 (2005).
Barcova, M. et al., “gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production.”Journal of Infectious Diseases, 177(4):905-13 (1998).
Biswas, P. S. et al., “Pathogen-specific CD8 T cell responses are directly inhibited by IL-10.”The Journal of Immunology, 179(7):4520-8 (2007).
Boland, A. and Cornelis , C.R., “Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection.”,Infection and Immunity, 66(5):1878-84 (1998).
Boussiotis, V. et al., “IL-10-producing T cells suppress immune responses in anergic tuberculosis patients” ,The Journal of Clinical Investigation, 105(9):1317-25 (2000).
Brady, M. T., A. J. MacDonald, et al. (2003). “Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes.”European Journal of Immunology, 33(12):3448-57 (2003).
Bray, M. et al.,“A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever” ,The Journal of Infectious Diseases, 178(3):651-61 (1998).
Brooks, D. G. et al., “Interleukin-10 determines viral clearance or persistence in vivo”,Nature Medicine, 12(11):1301-9 (2006).
Cappuccio, A. et al., “Determination of the optimal therapeutic protocols in cancer immunotherapy”,Mathematical Biosciences, 209(1):1-13 (2007).
Cornelis, G. R. and G. Denecker. “Yersinia lead SUMO attack”,Nature. Medicine, 7(1):21-3 (2001).
Crooke, S. T. Antisense Drug Technology: Principles, Strategies, and Applications. New York, Marcel Dekker, S. Crooke Ed Springer pp. 1-50 (1999).
Dercamp, C. et al., “Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses”,Cancer Research, 65(18):8479-86 (2005).
Ejrnaes, M. et al., “Resolution of a chronic viral infection after interleukin-10 receptor blockade”,The Journal of Experimental. Medicine, 203(11):2461-2472 (2006).
Encke, J. et al., “Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection”,Clinical and Experimental Immunology, 142(2):362-9 (2005).
Fleming S. B. et al., “A homolog of interleukin-10 is encoded by the poxvirus orf virus”,Jornal of Virology, 71(6):4857-61 (1997).
Gong, J. H. et al., “Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression”,Infection and Immunity, 64(3):913-8 (1996).
Guerrero-Plata, A. et al.,“Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus”,Am J Respir Cell Mol Biol., 34(3):320-9 (2006).
Igietseme, J. U. et al., “Suppression of Endogenous IL-10 Gene Expression in Dendritic Cells Enhances Antigen Presentation for Specific Th1 Induction: Potential for Cellular Vaccine Development”,The Journal of Immunology, 164(8):4212-4219 (2000).
Jacobs, M. et al.,“Increased resistance to mycobacterial infection in the absence of interleukin-10”,Immunology, 100(4): 494-501 (2000).
Kornbluth, R. S. and Stone, G.W., “Immunostimulatory combinations: designing the next generation of vaccine adjuvants”,Journal of Leukocyte Biology, 80(5):1084-102 (2006).
Koutsonikolis, A., S. Haraguchi, et al. (1997). “HIV-1 recombinant gp41 induces IL-10 expression and production in peripheral blood monocytes but not in T-lymphocytes.”Immunology Letters, 55(2):109-13 (1997).
Liu, G. et al., “Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response.”Eur J Immunol., 34(6):1680-7 (2004).
Marin-Serrano, E. et al., “Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin.”Journal of Viral Hepatitis, 13(4):230-4 (2006).
Marshall, N. B. et al., “Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.”Journal of Immunological Methods, 325(1-2):114-126 (2007).
Miyada, C. G. and Wallace, R.B., “Oligonucleotide hybridization techniques.”Methods in Enzymology, 154:94-107 (1987).
Mocellin, S. et al., “Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness.”Int J Cancer, 93(2):236-42 (2001).
Moore, K. W. et al., “Interleukin-10 and the interleukin-10 receptor.”Annu Rev Immunol., 19:683-765 (2001).
Murray, P. J. and Young, R.A., “Increased antimycobacterial immunity in interleukin-10-deficient mice.”Infection and Immunity, 67(6):3087-95 (1999).
Nielsen, E., “RNA targeting using peptide nucleic acid.”Handb Exp Pharmacol., 173:395-403 (2006).
Nigou, J. et al., “Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor.”The Journal of Immunology, 166(12):7477-85 (2001).
Oh, J. H. et al., “Polymorphisms of interleukin-10 and t
Iversen Patrick L.
Mourich Dan V.
AVI BioPharma Inc.
Navarro Albert
Seed IP Law Group PLLC
LandOfFree
Immunomodulatory agents and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulatory agents and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory agents and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2785355